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Abstract 
 Alzheimer’s disease (AD) is the most common form of dementia and cerebrospinal 
ﬂuid (CSF) biomarkers reﬂecting the core pathology of AD are now widely used for 
diagnosis making, in particular β-amyloid1-42 (Aβ42) reﬂecting amyloid plaque 
pathology, phosphorylated tau (P-tau) reﬂecting neuroﬁbrillary tangle pathology and 
total tau (T-tau) reﬂecting general neurodegeneration. In addition, blood-based 
biomarkers for AD are in the pipeline with recent studies showing promising 
diagnostic potential. �e most important genetic risk factor for sporadic AD is the ε4 
allele of the apolipoprotein E (APOE) polymorphism, increasing risk for AD diagnosis 
in a dose-dependent manner as well as lowering the age of onset. 
 We conducted a comprehensive meta-analysis of the AD biomarker literature from 
1984 to 2014, which could conﬁrm the robust diagnostic performance of the above-
mentioned established CSF biomarker triad for AD, and also revealed possible new 
biomarker candidates in both CSF and blood that could contribute to the diagnostic 
work-up of the disease as well as serve as tools for monitoring new disease-modifying 
treatments. In a large multicentre study, we conﬁrmed the strong association between 
the APOE ε4 genotype and AD and showed that the ε4 allele also aﬀects 
concentrations of CSF Aβ42 in a dose-dependent manner. However, the APOE 
polymorphism does not blur the diagnostic accuracy of the established AD biomarkers 
and CSF Aβ42 was shown to reﬂect cerebral amyloid pathology irrespective of the 
APOE genotype. In another multicentre cohort consisting of solely cognitively healthy 
subjects, we showed that the dose-dependent eﬀect of APOE ε4 on CSF Aβ42 was 
absent in younger subjects and CSF Aβ42 concentrations started to drop around age 50 
and even earlier in ε4-carriers, pinpointing the earliest disturbances in amyloid 
homeostasis, long before cognitive impairment becomes apparent. 
 Taken together, the results from this thesis underline the usefulness of AD 
biomarkers as well as their robust diagnostic performance irrespective of the most 
prominent genetic risk factor. In addition, since biomarkers (in particular CSF Aβ42) 
can reﬂect pathological changes already in the preclinical stage of the disease, they 
could become valuable in future AD prevention, once disease-modifying therapies 
become available.  
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